Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies

Cancer Medicine
Aurélie Cabannes-Hamylymphoma study association

Abstract

CNS relapse is reported in 2-5% of diffuse large B-cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk factors of CNS relapse in very elderly patients, a challenging population to treat given their commonly associated comorbidities. A retrospective analysis was performed of 270 DLBCL patients >80 years treated between 2004 and 2013 in two multicentre phase II LYSA trials (LNH03-7B, LNH09-7B) evaluating the addition of rituximab or ofatumumab to mini-CHOP as front-line therapy. No patients received CNS prophylaxis. CNS relapse was evaluated according to cumulative incidence, patient characteristics, risk factors, and survival. Median age was 83 years (range: 79-95). After a median follow-up of 28.7 months, eight patients had CNS relapse (3.0%). Median time between inclusion and CNS relapse was 19.2 months (range: 3.2-32.6). Patients survived a median of 1.5 months after CNS relapse (range: 0.4-4.1). Median OS from relapse was significantly lower in CNS relapse patients (1.5 months, 95% CI: 0.4-3.5) compared to patients with non-CNS relapse (6.6 months; 95% CI: 4.6-11.9). No baseline characteristics were associated with CNS relapse. The proportion of patients ...Continue Reading

References

Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Aug 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HollenderH Holte
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P FeugierB Coiffier
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Dec 11, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ThieblemontB Coiffier
Oct 29, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D VillaK J Savage
Apr 13, 2011·The Lancet Oncology·Frédéric PeyradeUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators
Aug 1, 2012·The Lancet Oncology·Frédéric PeyradeAntoine Thyss
Aug 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A TrebouetR Houot
Sep 17, 2013·British Journal of Haematology·Andrew McMillanUNKNOWN British Committee for Standards in Haematology
Jul 7, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norbert SchmitzKerry J Savage

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Clinical Trials Mentioned

NCT01087424
NCT01195714
NCT02128061

Software Mentioned

SAS

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.